Rex Bionics : Notification of Interim Results

1 July 2014

Rex Bionics plc

("Rex Bionics" or the "Company")

Notification of Interim Results

Rex Bionics plc (AIM: RXB), the developer and manufacturer of REX products: hands-free robotic exoskeletons for use by wheelchair users,will issue its Interim Results for the six month period ending 31 May 2014 on Tuesday 5 August, 2014. 

Jeremy Curnock Cook, Chief Executive Officer, and Peter Worrall, Chief Financial Officer, will host an analyst briefing at 10am BST at Consilium Strategic Communications' offices at 1 Cornhill, EC3V 3ND, where they will present the financial and operational results followed by a Q&A session.

For further information please contact:

Rex Bionics Plc

Jeremy Curnock Cook, Chief Executive Officer

+44 (0) 781 086 6386

Peter Worrall, Chief Financial Officer

+44 (0)1428 645416

Oriel Securities Limited (NOMAD and Broker)

Juliet Thompson/Jonathan Senior

+44 (0) 20 7710 7600

Consilium Strategic Communications

Mary-Jane Elliott / Emma Thompson / Jessica Hodgson / Lindsey Neville

rexbionics@consilium-comms.com

+44 (0) 203 709 5700

About Rex Bionics

Rex Bionics (AIM: RXB) is an AIM-listed developer and manufacturer of REX products, hands-free robotic exoskeletons for use by people with mobility impairments. Founded in Auckland, New Zealand by two robotics engineers with first-hand experience of wheelchair users and their needs, Rex Bionics focuses on products designed to enable wheelchair users to stand and walk autonomously without the need for crutches or supports and is the only company to produce hands-free walking devices for wheelchair users. Rex Bionics' marketed products: REX Rehab and REX Personal, can be used by people with complete spinal cord injury, but also by a much broader potential customer base, including people with multiple sclerosis and muscular dystrophy. In May 2014, Rex Bionics joined AIM with a fundraising of £10 million (gross) to scale up production, distribution and marketing internationally, in order to support growing demand for both REX products as well as developing the next generation of REX devices, REX 3.

For more information please visit, www.rexbionics.com